Foundational guide
FOXO4-DRI Before and After: What Was Measured, and In What
The images attached to this compound are genuine published figures. They are photographs of mouse coats, and the endpoints behind them require instrumentation no reader has.
There are no FOXO4-DRI before and after results in humans, because no human has received the compound in a registered study. The images genuinely associated with it are published figures showing mice.
More useful than that correction is examining what the studies measured, because most of the endpoints are not the sort of thing anyone could observe.
Supplier publishing lot-level data
FOXO4-DRI, Ascension Peptides
Two independent laboratories have certified this product, though on different batches. The code below halves the listed price on the vial.
The two published certificates cover different lots and disagree on fill: Kovera Labs assays batch 55-05260628 at 11.41 mg, MZ Biolabs assays lot 55-01260229 at 8.30 mg, both against a 10 mg label, moving the real figure between $5.87/mg and $8.07/mg. Endotoxin and sterility screens appear on the Kovera lot only, so testing scope here is a batch property rather than a product feature. The vendor spells the product FOX04 with a zero, including in the link.
- Kovera Labs and MZ Biolabs certificates, different lots
- Carriage free above $250
- Same-day dispatch before 2pm CST
Laboratory research material only, not for human consumption. FOXO4-DRI holds no marketing authorisation in any market and has never been administered in a registered human trial. Affiliate links: we may earn a commission at no additional cost to you. Figures checked September 2, 2026.
The endpoints, and what each required
Listing the measurements rather than describing the results makes the gap obvious.
Only one row in that table is visible to the eye, and it is the one that produced the circulating images.
| Endpoint | Instrumentation required | Organism |
|---|---|---|
| Senescent-cell burden | p16-driven bioluminescent reporter, in vivo imaging | Mouse |
| Senescence markers | SA-beta-gal staining, p16 and p21 quantification | Mouse, cultured cells |
| Fur density | Photography and scoring | Mouse |
| Physical fitness | Performance apparatus | Mouse |
| Renal function | Biochemical assay | Mouse |
| Cell viability | In-vitro viability assay | Cultured cells |
| Any human outcome | Not measured | None |
Why fur density became the famous result
Restored coat density in aged and fast-ageing mice is a legitimate endpoint. It is a visible correlate of tissue maintenance in an animal with a defined genetic background, controlled diet and short lifespan, and it was measured and scored rather than merely observed.
It is also the only endpoint in the study that photographs well, which is why it dominated press coverage and why those images continue to circulate detached from their caption.
The interpretive error is treating a rodent healthspan proxy as a human transformation. Fur density was selected because it is measurable and meaningful within that model, not because it corresponds to anything a person would recognise as an outcome.
Why no timeline can be stated
A before-and-after claim requires a subject, a defined exposure, a defined interval, a measured endpoint and ideally a control. Each element is missing here.
There is no defined dose, since none is established in humans. There is no expected interval, since no human pharmacokinetic data exists and the persistence of a protease-resistant peptide in a human body has never been determined. There is no observable endpoint, as the table above shows. And there is no control, so an individual change could not be attributed to the compound even if one occurred.
Any timeline encountered for this compound was therefore authored rather than measured.
Reading the anecdotal literature
Self-reported accounts are the only human-adjacent material available, and they cannot bear the weight placed on them.
The compounding problem is confounding. A person using an unapproved research peptide is typically also modifying training, diet and sleep, and frequently using several compounds concurrently. Attributing a change to one variable is not possible in that design, irrespective of the reporter's honesty.
The material itself is also unverified. Without a lot-matched certificate, the composition and quantity of what was used are unknown, and for this product the published batches differ by 37% in net content.
A 2023 study additionally found that clearing senescent cells could worsen pulmonary hypertension, so favourable self-reports would not by themselves establish that the intervention is benign.
Frequently asked questions
- Are there human before and after results for FOXO4-DRI?
- No. No person has received this compound in a registered study, so no human outcome has been measured on any timescale.
- What do the circulating photographs show?
- Mice. The 2017 study reported and photographed restored fur density in aged and fast-ageing animals, and those figures continue to circulate detached from their original caption.
- Could I assess whether it is working?
- No. The endpoints used require bioluminescent reporters, senescence marker staining and biochemical assays. None is observable outside a laboratory.
- Why are self-reported accounts unreliable here?
- They are confounded by concurrent changes in training, diet and other compounds, and the material used is typically unverified. For this product, published batches differ by 37% in net content.
Limitations of the evidence
No human outcome data exists for FOXO4-DRI on any timescale. The endpoints described here are laboratory measurements in animal and in-vitro models and are not observable outside that setting. No timeline for a human effect can be given because none has been measured.
References
Citations are annotated with an evidence tier reflecting study design and replication. See Methodology for criteria.
- 1.Baar MP, Brandt RMC, Putavet DA, et al. · Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging · Cell · 2017PMID 28340339Preclinical
- 2.Frontiers in Bioengineering and Biotechnology · Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes · Frontiers in Bioengineering and Biotechnology · 2021PMID 33996787Preclinical
- 3.Circulation · Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression · Circulation · 2023PMID 36515093Preclinical